

**Summary of Consolidated Financial Results [IFRS]
for the First Six Months (Semi-Annual Period) of the Fiscal Year Ending March 31, 2025**

November 6, 2024

Listed company name : Sysmex Corporation
Code : 6869
Listed stock exchanges : Tokyo Stock Exchange
URL : www.sysmex.co.jp/en
Company representative : Kaoru Asano, President
Contact : Takuro Minami, Executive Vice President of
Corporate Business Administration
Phone : 078(265)-0500
Scheduled date for filing of semi-annual report : November 8, 2024
Scheduled date for dividend payment : December 3, 2024
Preparation of supplementary material for
semi-annual earnings : Yes
Holding of earnings announcement : Yes

(Unit: Millions of Yen)

1. Results for the First Six Months (Semi-Annual Period) of the Fiscal Year Ending March 31, 2025

(1) Operating results

(% changes as compared with the semi-annual period of the previous fiscal year)

	Net Sales		Operating profit		Profit before tax		Profit	
Six months ended Sep. 30, 2024	242,479	14.0%	44,502	31.6%	38,280	15.0%	25,923	17.0%
Six months ended Sep. 30, 2023	212,698	9.6%	33,824	2.0%	33,300	(3.6)%	22,154	(7.4)%

	Profit attributable to owners of the parent		Total comprehensive income		Basic earnings per share (Yen)	Diluted earnings per share (Yen)
Six months ended Sep. 30, 2024	26,002	17.2%	17,536	(56.4)%	41.70	41.70
Six months ended Sep. 30, 2023	22,186	(7.5)%	40,201	2.1%	35.34	35.32

Note: The Company conducted a three-for-one stock split on common stock with an effective date of April 1, 2024. Basic earnings per share and diluted earnings per share have been calculated as if the stock split had taken place at the beginning of the previous consolidated fiscal year.

(2) Financial condition

	Total assets	Total equity	Equity attributable to owners of the parent	Equity attributable to owners of the parent to total assets
As of Sep. 30, 2024	618,061	441,720	440,948	71.3%
As of Mar. 31, 2024	618,920	432,897	432,045	69.8%

2. Dividend

	Dividend per share				
	First quarter (Yen)	Second quarter (Yen)	Third quarter (Yen)	Year-end (Yen)	Annual (Yen)
Year ended Mar. 31, 2024	—	42.00	—	42.00	84.00
Year ending Mar. 31, 2025	—	15.00			
Year ending Mar. 31, 2025 (Forecast)			—	15.00	30.00

Notes:

1. Revision of dividends forecast for this period: No
2. The Company conducted a three-for-one stock split on common stock with an effective date of April 1, 2024. However, actual dividend amounts prior to this stock split are shown for the fiscal years ended March 31, 2024.

3. Financial Forecast for the Year Ending March 31, 2025

(% changes as compared with the previous fiscal year)

	Net Sales		Operating profit		Profit before tax		Profit attributable to owners of the parent		Basic earnings per share (Yen)
	Year ending Mar. 31, 2025	510,000	10.5%	90,000	14.8%	82,500	10.6%	55,000	10.8%

Note: Revision of financial forecast for this period: Yes

4. Other Information

- (1) Significant changes in scope of consolidation: No
- (2) Changes in accounting policies and accounting estimates
 - 1) Changes in accounting policies required by IFRS: No
 - 2) Other changes in accounting policies: No
 - 3) Changes in accounting estimates: No
- (3) Number of outstanding stock (common stock)
 - 1) Number of outstanding stock at the end of each fiscal period (including treasury stock):
629,372,616 shares as of Sep.30, 2024; 629,371,116 shares as of Mar. 31, 2024
 - 2) Number of treasury stock at the end of each fiscal period:
5,873,311 shares as of Sep. 30, 2024; 5,872,332 shares as of Mar. 31, 2024
 - 3) Average number of outstanding stock for each period (semi-annual period):
623,498,618 shares for the six months ended Sep. 30, 2024
627,845,650 shares for the six months ended Sep. 30, 2023

Notes:

1. The Company has introduced Stock-Granting Employee Stock Ownership Plan (ESOP) Trust. Company shares held by the trust are included in treasury stock and are excluded from calculations of the number of treasury stock at the end of the fiscal period and the average number of outstanding stock for the period.
2. The Company conducted a three-for-one stock split on common stock with an effective date of April 1, 2024. The number of outstanding stock at the end of the fiscal period, the number of treasury stock at the end of the fiscal period, and the average number of outstanding stock for the period are calculated as if the stock split had taken place at the beginning of the previous consolidated fiscal year.

* Summaries of semi-annual financial results are exempt from review conducted by certified public accountants or an audit firm.

* Explanation regarding the appropriate use of financial forecast and other information

1. The forecasts and future projections contained herein have been prepared on the basis of rational decisions given the information available as of the date of announcement of this document. These forecasts do not represent a commitment by the Company, and actual performance may differ substantially from forecasts for a variety of reasons. Please refer to “3) Consolidated financial forecast” within “1. Qualitative information on semi-annual financial results” on page 4 of the attachment to this document for cautionary statements concerning the conditions and performance forecasts that serve as the basis for these forecasts.
2. Supplementary financial materials (in Japanese and English) will be posted on the Sysmex website on Wednesday, November 6, 2024.

Content of Supplementary Materials

1. Qualitative information on semi-annual financial results	2
1) Operating performance analysis	2
2) Financial conditions analysis	4
3) Consolidated financial forecast	5
2. Condensed semi-annual consolidated financial statements and notes	5
1) Condensed semi-annual consolidated statement of financial position	5
2) Condensed semi-annual consolidated statement of income	7
3) Condensed semi-annual consolidated statement of comprehensive income	8
4) Condensed semi-annual consolidated statement of changes in equity	9
5) Condensed semi-annual consolidated statement of cash flows	11
6) Notes to the condensed semi-annual consolidated financial statements	12
1. Notes related to the going concern assumption	12
2. Segment information	12

1. Qualitative information on semi-annual financial results

1) Operating performance analysis

Future-related information contained in the text below is based on the Company's judgement as of the end of the fiscal period under review.

During the first six months of the fiscal year ending March 31, 2025, we expected the global economy to continue growing at a pace similar to the fiscal year ended March 31, 2024, supported by increased government spending, household consumption, and expanded supply capacity driven by rising labor market participation rates. However, upward pressure on service prices is hindering the progress of disinflation, and the risk of inflationary pressures is likely to persist.

On the healthcare front, as global society ages we expect to see efforts to optimize social security expenditures and decentralize healthcare functions. Against this backdrop, prevention and self-medication will become increasingly important. At the same time, healthcare disparities and the issue of accessibility to healthcare will continue to persist. Furthermore, we anticipate advancements in technological innovation such as gene analysis, ultrahigh sensitive measurement, and miniaturization, which will be applied to healthcare. Demand for personalized medicine will grow, and we expect the practical application of new treatment methods such as regenerative and cellular medicine and genomic medicine. Additionally, we predict the widespread adoption of artificial intelligence (AI) and the acceleration of digital transformation (DX) in the healthcare sector, including the implementation and expansion of robotic technologies. We anticipate further growth opportunities as a result.

Against this backdrop, Sysmex completed construction of a new manufacturing base in India, which is the Group's first factory capable of producing both reagents and instruments. The new manufacturing base has the largest total floor area of all the Sysmex Group's manufacturing bases outside Japan. It has the capacity to significantly expand the range of reagents produced and to produce instrument products in response to the Make in India policy of the Government of India. This will strengthen our supply capacity for robust testing demand and aim for accelerated business expansion and sustained growth in India. We will proceed with preparations for full-scale operations and plan to begin shipping both reagents and instruments from the new manufacturing by the end of fiscal year 2024.

In addition, Sysmex has expanded its strategic alliance agreement with QIAGEN N.V. to deepen their collaboration in genetic testing, including research and development, production, clinical development, and sales-marketing. As part of the newly expanded collaboration, both companies will further combine their respective products and strengths in genetic testing to deliver high-value products to their global customers, and will consider future collaboration in product development. As one aspect of this collaboration, Sysmex will implement QIAGEN's assay to be used for clinical trials that QIAGEN provides to pharmaceutical companies and research institutions at Sysmex's global network laboratories (Sysmex Inostics, Inc. CLIA lab*¹, Sysmex Research and Development Center and Sysmex affiliated company, RIKEN GENESIS Co., Ltd., and support QIAGEN's global services.

In September 27, 2024, Sysmex launched the HISCL™ HIT IgG Assay Kit for measuring IgG antibodies against the complexes of platelet factor 4 and heparin in the Japanese market. The assay kit is for our Automated Blood Coagulation Analyzers CN™-6500/CN™-3500 that incorporate the technology of the HISCL™-Series*². It achieves the high sensitivity and high specificity required in serological testing for heparin-induced thrombocytopenia (HIT*³). By achieving high specificity, the assay kit reduces false positives, which are an issue in determining adverse reactions to heparin therapy. This, in turn, speeds up the diagnosis of HIT and enhances testing efficiency.

*1 CLIA lab:

A laboratory certified under the US Clinical Laboratory Improvement Amendment (CLIA). Certified laboratories are required to maintain quality through regular inspections, etc., and this guarantees quality control in testing.

*2 HISCL™-Series:

A generic term for the Automated Immunoassay Systems HISCL™-5000/HISCL™-800.

*3 HIT:

A disease in which the use of heparin causes thrombocytopenia and thrombosis.

Net sales by destination

	Six months ended Sep. 30, 2023		Six months ended Sep. 30, 2024		YoY (Previous period = 100)
	Amount (Millions of yen)	Percentage of total (%)	Amount (Millions of yen)	Percentage of total (%)	
Japan	27,668	13.0	30,323	12.5	109.6
Americas	57,209	26.9	63,745	26.3	111.4
EMEA	59,593	28.0	69,121	28.5	116.0
China	47,514	22.4	54,540	22.5	114.8
Asia Pacific	20,712	9.7	24,748	10.2	119.5
Overseas subtotal	185,030	87.0	212,156	87.5	114.7
Total	212,698	100.0	242,479	100.0	114.0

In Japan, we experienced higher sales of hematology instruments and reagents, and in the medical robotics business, sales of instruments and consumables rose. As a result, sales in Japan increased 9.6% year on year, to ¥30,323 million.

Overseas, sales of reagents and maintenance services increased in the hematology field, as did sales of hemostasis and urinalysis reagents. These factors, plus ongoing yen depreciation, caused overseas sales to rise 14.7% year on year, to ¥212,156 million. The overseas sales ratio rose 0.5 percentage point, to 87.5%.

Selling, general and administrative (SG&A) expenses expanded 15.6%, to ¥72,371 million. Behind this rise were an increase in personnel numbers in line with business expansion and sales promotion activities. R&D expenses increased 1.5% year on year, to ¥15,239 million.

As a result, during the first six months of the fiscal year ending March 31, 2025, Sysmex recorded consolidated net sales of ¥242,479 million, up 14.0% year on year. Operating profit was up 31.6%, to ¥44,502 million; profit before tax increased 15.0%, to ¥38,280 million, and profit attributable to owners of the parent rose by 17.2%, to ¥26,002 million.

Performance by segment

(1) Headquarters

Sales of hematology and hemostasis instruments and reagents expanded. Consequently, sales increased 12.6% year on year, to ¥43,336 million.

On the profit front, SG&A expenses rose, but higher sales and an improved cost of sales ratio pushed up segment profit (operating profit) 32.2%, to ¥27,595 million.

(2) Americas RHQ

In North America, sales of hematology and urinalysis reagents and maintenance services rose. In Central and South America, centered on the Brazilian market, sales of hematology instruments and reagents grew, and sales of urinalysis reagents increased. As a result, overall sales in the Americas grew 10.6% year on year, to ¥59,804 million.

Despite the higher sales, segment profit (operating profit) fell 36.8%, to ¥3,178 million, owing to higher SG&A expenses.

(3) EMEA RHQ

Benefiting from the effect of the transition to direct sales in Saudi Arabia, sales of hematology instruments and reagents grew, as did sales of hemostasis reagents. Accordingly, sales were ¥66,482 million, up 14.3% year on year.

Although SG&A expenses rose, higher sales caused segment profit (operating profit) to soar 46.9%, to ¥6,785 million.

(4) China RHQ

Sales of hematology and hemostasis reagents increased, buoyed by a rise in the number of

tests. Consequently, sales rose 14.8%, to ¥54,471 million.

Segment profit (operating profit) surged 48.2% year on year, to ¥5,812 million, owing to higher sales and lower selling, general and administrative (SG&A) expenses.

(5) Asia Pacific RHQ

Benefiting from growth in the Indian market, sales of hematology reagents and maintenance services increased. As a result, sales were ¥18,384 million, up 26.5% year on year.

Segment profit (operating profit) expanded 100.3% year on year, to ¥3,740 million, thanks to higher sales and an improved cost of sales ratio.

2) Financial conditions analysis

(1) Financial conditions

As of September 30, 2024, total assets amounted to ¥618,061 million, down ¥859 million from March 31, 2024. As main factors, trade and other receivables (current assets) decreased ¥19,468 million, while cash and cash equivalents increased ¥16,211 million, and inventories increased ¥3,392 million.

Meanwhile, total liabilities as of September 30, 2024 were ¥176,341 million, down ¥9,682 million from March 31, 2024. Among principal changes, trade and other payables were down by ¥6,237 million, non-current lease liabilities by ¥2,335 million, and accrued bonuses by ¥2,147 million, while long-term loans payable were up ¥2,969 million.

Total equity came to ¥441,720 million, up ¥8,822 million from March 31, 2024. Among principal reasons, retained earnings increased ¥18,635 million, while other components of equity decreased ¥9,747 million. Equity attributable to owners of the parent to total assets amounted to 71.3% on September 30, 2024, up 1.5 percentage points from 69.8% on March 31, 2024.

(2) Cash flows

As of September 30, 2024, cash and cash equivalents amounted to ¥91,719 million, up ¥16,211 million from March 31, 2024.

Cash flows from various activities during the first six months of the fiscal year are described in more detail below.

(Cash flows from operating activities)

Net cash provided by operating activities was ¥50,131 million, up ¥19,460 million from the same period of the previous fiscal year. As principal factors, profit before tax provided ¥38,280 million (¥4,980 million more than in the same period of the preceding year), depreciation and amortization provided ¥19,191 million (up ¥2,115 million), and an increase in inventories used ¥7,414 million (up ¥3,797 million).

(Cash flows from investing activities)

Net cash used in investing activities was ¥23,758 million (up ¥256 million). Among major factors, purchases of property, plant and equipment used ¥11,490 million (up ¥938 million), and purchases of intangible assets used ¥11,845 million (up ¥186 million).

(Cash flows from financing activities)

Net cash used in financing activities was ¥10,532 million (down ¥2,276 million). This was mainly due to dividends paid of ¥8,728 million (down ¥59 million).

3) Consolidated financial forecast

For the Company's consolidated financial forecast for the full fiscal year, please refer to the Announcement Regarding Differences between Actual and Forecast Figures for the Six Months Ended September 30, 2024, and Revision of Full Year Financial Forecasts, announced today (November 6, 2024).

2. Condensed semi-annual consolidated financial statements and notes

1) Condensed semi-annual consolidated statement of financial position

(Unit: Millions of yen)

	As of March 31, 2024	As of September 30, 2024
Assets		
Current assets		
Cash and cash equivalents	75,507	91,719
Trade and other receivables	157,067	137,599
Inventories	79,123	82,516
Other short-term financial assets	1,310	1,284
Income taxes receivable	934	1,499
Other current assets	29,515	27,890
Total current assets	343,459	342,509
Non-current assets		
Property, plant and equipment	116,693	113,566
Goodwill	17,221	17,049
Intangible assets	86,786	89,689
Investments accounted for using the equity method	472	408
Trade and other receivables	21,435	22,920
Other long-term financial assets	14,034	11,585
Asset for retirement benefits	458	495
Other non-current assets	4,339	4,218
Deferred tax assets	14,018	15,619
Total non-current assets	275,461	275,552
Total assets	618,920	618,061

(Unit: Millions of yen)

	As of March 31, 2024	As of September 30, 2024
Liabilities and equity		
Liabilities		
Current liabilities		
Trade and other payables	33,602	27,365
Lease liabilities	8,659	8,362
Other current financial liabilities	1,028	1,432
Income taxes payable	12,476	12,793
Provisions	1,159	1,145
Contract liabilities	16,591	16,264
Accrued expenses	21,643	20,543
Accrued bonuses	12,611	10,463
Other current liabilities	10,311	9,031
Total current liabilities	118,084	107,403
Non-current liabilities		
Long-term loans payable	28,600	31,569
Lease liabilities	18,080	15,745
Other non-current financial liabilities	76	66
Liability for retirement benefits	2,239	2,398
Provisions	674	682
Other non-current liabilities	10,350	11,103
Deferred tax liabilities	7,917	7,371
Total non-current liabilities	67,938	68,937
Total liabilities	186,023	176,341
Equity		
Equity attributable to owners of the parent		
Capital stock	14,729	14,732
Capital surplus	20,830	20,846
Retained earnings	365,985	384,620
Treasury stock	(12,315)	(12,318)
Other components of equity	42,814	33,066
Total equity attributable to owners of the parent	432,045	440,948
Non-controlling interests	851	772
Total equity	432,897	441,720
Total liabilities and equity	618,920	618,061

2) Condensed semi-annual consolidated statement of income

(Unit: Millions of yen)

	Six months ended September 30, 2023	Six months ended September 30, 2024
Net sales	212,698	242,479
Cost of sales	101,684	111,184
Gross profit	111,014	131,295
Selling, general and administrative expenses	62,591	72,371
Research and development expenses	15,012	15,239
Other operating income	861	1,191
Other operating expenses	447	373
Operating profit	33,824	44,502
Financial income	582	520
Financial expenses	963	1,421
Share of profit (loss) of associates accounted for using the equity method	(1,495)	(1,290)
Foreign exchange gain (loss)	1,351	(4,030)
Profit before tax	33,300	38,280
Income taxes expenses	11,145	12,357
Profit	22,154	25,923
Profit attributable to		
Owners of the parent	22,186	26,002
Non-controlling interests	(32)	(79)
Profit	22,154	25,923
		(Unit: Yen)
Earnings per share		
Basic	35.34	41.70
Diluted	35.32	41.70

3) Condensed semi-annual consolidated statement of comprehensive income

(Unit: Millions of yen)

	Six months ended September 30, 2023	Six months ended September 30, 2024
Profit	22,154	25,923
Other comprehensive income		
Items that will not be reclassified subsequently to profit or loss		
Net gain (loss) on financial assets measured at fair value through other comprehensive income	508	(1,550)
Total	508	(1,550)
Items that may be reclassified subsequently to profit or loss		
Exchange differences on translation of foreign operations	17,529	(6,826)
Share of other comprehensive income of investments accounted for using the equity method	8	(9)
Total	17,538	(6,836)
Total other comprehensive income	18,046	(8,386)
Comprehensive income	40,201	17,536
Comprehensive income attributable to		
Owners of the parent	40,233	17,616
Non-controlling interests	(32)	(79)
Comprehensive income	40,201	17,536

4) Condensed semi-annual consolidated statement of changes in equity
Six months ended September 30, 2023

(Unit: Millions of yen)

	Equity attributable to owners of the parent						Non-controlling interests	Total equity
	Capital stock	Capital surplus	Retained earnings	Treasury stock	Other components of equity	Total		
As of April 1, 2023	14,282	20,580	334,192	(314)	18,925	387,665	690	388,356
Profit	—	—	22,186	—	—	22,186	(32)	22,154
Other comprehensive income	—	—	—	—	18,046	18,046	0	18,046
Comprehensive income	—	—	22,186	—	18,046	40,233	(32)	40,201
Exercise of warrants	268	153	—	—	—	421	—	421
Share-based payment transactions	—	—	—	—	—	—	—	—
Cash dividends	—	—	(8,788)	—	—	(8,788)	—	(8,788)
Purchase of treasury stock	—	—	—	(0)	—	(0)	—	(0)
Disposal of treasury stock	—	—	—	—	—	—	—	—
Changes due to acquisition of control of a subsidiary	—	(5)	—	—	—	(5)	(62)	(67)
Changes due to loss of control of a subsidiary	—	—	—	—	—	—	(0)	(0)
Transfer to retained earnings	—	—	—	—	—	—	—	—
Total transactions with the owners	268	147	(8,788)	(0)	—	(8,372)	(62)	(8,435)
As of September 30, 2023	14,550	20,728	347,590	(315)	36,972	419,526	596	420,122

Six months ended September 30, 2024

(Unit: Millions of yen)

	Equity attributable to owners of the parent						Non-controlling interests	Total equity
	Capital stock	Capital surplus	Retained earnings	Treasury stock	Other components of equity	Total		
As of April 1, 2024	14,729	20,830	365,985	(12,315)	42,814	432,045	851	432,897
Profit	—	—	26,002	—	—	26,002	(79)	25,923
Other comprehensive income	—	—	—	—	(8,386)	(8,386)	—	(8,386)
Comprehensive income	—	—	26,002	—	(8,386)	17,616	(79)	17,536
Exercise of warrants	2	1	—	—	—	3	—	3
Share-based payment transactions	—	14	—	—	—	14	—	14
Cash dividends	—	—	(8,728)	—	—	(8,728)	—	(8,728)
Purchase of treasury stock	—	—	—	(2)	—	(2)	—	(2)
Disposal of treasury stock	—	0	—	0	—	0	—	0
Changes due to acquisition of control of a subsidiary	—	—	—	—	—	—	—	—
Changes due to loss of control of a subsidiary	—	—	—	—	—	—	—	—
Transfer to retained earnings	—	—	1,361	—	(1,361)	—	—	—
Total transactions with the owners	2	15	(7,367)	(2)	(1,361)	(8,713)	—	(8,713)
As of September 30, 2024	14,732	20,846	384,620	(12,318)	33,066	440,948	772	441,720

5) Condensed semi-annual consolidated statement of cash flows

(Unit: Millions of yen)

	Six months ended September 30, 2023	Six months ended September 30, 2024
Cash flows from operating activities		
Profit before tax	33,300	38,280
Depreciation and amortization	17,075	19,191
Share of loss (profit) of associates accounted for using the equity method	1,495	1,290
Loss on retirement of non-current assets	231	64
Decrease (increase) in trade receivable	3,112	16,593
Decrease (increase) in advance payments	(732)	326
Decrease (increase) in inventories	(3,617)	(7,414)
Increase (decrease) in trade payable	252	(1,648)
Increase (decrease) in accounts payable—other	(2,568)	(1,758)
Increase (decrease) in contract liabilities	(1,146)	361
Increase (decrease) in accrued expenses	556	(417)
Decrease/increase in consumption taxes receivable/payable	2,897	419
Increase (decrease) in accrued bonuses	(2,612)	(2,039)
Other—net	(2,007)	869
Subtotal	46,238	64,118
Interest and dividend received	264	284
Interest paid	(555)	(816)
Income taxes paid	(15,276)	(13,455)
Net cash provided by (used in) operating activities	30,671	50,131
Cash flows from investing activities		
Purchases of property, plant and equipment	(10,552)	(11,490)
Purchases of intangible assets	(11,659)	(11,845)
Payments resulting in an increase in long-term prepaid expenses	(294)	(326)
Purchases of investments in equity instruments	(273)	(1,933)
Proceeds from the sale of equity instruments	—	1,853
Purchase of investments in debt instruments	—	(399)
Acquisitions of subsidiaries or other businesses	(621)	—
Payments into time deposits	(817)	(872)
Proceeds from withdrawal of time deposits	852	1,007
Other—net	(135)	249
Net cash provided by (used in) investing activities	(23,502)	(23,758)
Cash flows from financing activities		
Proceeds from long-term loans payable	—	3,500
Repayments of long-term loans payable	—	(296)
Exercise of warrants	421	3
Dividends paid	(8,788)	(8,728)
Repayments of lease liabilities	(4,374)	(5,008)
Other—net	(68)	(2)
Net cash provided by (used in) financing activities	(12,809)	(10,532)
Effects of exchange rate changes on cash and cash equivalents	4,788	371
Net increase (decrease) in cash and cash equivalents	(851)	16,211
Cash and cash equivalents at the beginning of the term	69,460	75,507
Cash and cash equivalents at the end of the term	68,608	91,719

6) Notes to the condensed semi-annual consolidated financial statements

1. Notes related to the going concern assumption

Not applicable

2. Segment information

1) Overview of reportable segments

The Group's reportable segments are the constituent business units of the Group for which separate financial data are available and that are examined on a regular basis for the purpose of enabling the Managing Board to allocate managerial resources and evaluate results of operations.

The Group is primarily engaged in the manufacture and sale of diagnostic instruments and reagents. These businesses are conducted in Japan and East Asia by Sysmex and in the Americas, EMEA, China, and the Asia Pacific by regional headquarters established therein. These companies formulate comprehensive strategies tailored to regional characteristics and conduct business activities accordingly. Some overseas subsidiaries are managed by Sysmex depending on the nature of their business.

To date, we have organized reportable segments geographically. However, from the semi-annual period under review, we have integrated our performance management system to focus on managing company-specific segments in the interest of making performance management more efficient. We have revised the reportable segments based on this management approach. The five managing company-specific segments are "Headquarters," "Americas RHQ," "EMEA RHQ," "China RHQ," and "AP RHQ."

The companies included in these reportable segments are outlined below.

Reportable segments	Companies included in the reportable segments
Headquarters	Sysmex Corporation, Sysmex RA Co., Ltd., 12 other domestic subsidiaries, Oxford Gene Technology IP Limited, Sysmex Partec GmbH, Sysmex Korea Co., Ltd., 12 other overseas subsidiaries
Americas RHQ	Sysmex America, Inc., Sysmex Reagents America, Inc., Sysmex do Brasil Industria e Comercio Ltda., five other subsidiaries in the Americas
EMEA RHQ	Sysmex Europe SE, Sysmex Deutschland GmbH, 26 other subsidiaries in the EMEA region
China RHQ	Sysmex Shanghai ltd., Jinan Sysmex Medical Electronics Co., Ltd., two other subsidiaries in China
AP RHQ	Sysmex Asia Pacific Pte Ltd., Sysmex India Pvt. Ltd., nine other subsidiaries in the Asia Pacific region

2) Segment profit and operating results

Profit and operating results from continuing operations by reportable segment of the Group are as follows:

Intersegment sales are determined based on market prices or costs of goods manufactured.

Accounting policies of reporting segments are consistent with the Group's accounting policies indicated in the consolidated financial statements for the previous fiscal year

Segment information for the previous semi-annual period is based on the revised reportable segment categories.

Six months ended September 30, 2023

(Unit: Millions of yen)

	Reportable segment						Adjustments (Note 1)	Consolidated (Note 2)
	Head- quarters	Americas RHQ	EMEA RHQ	China RHQ	AP RHQ	Total		
Sales								
Sales to external customers	38,472	54,058	58,180	47,450	14,537	212,698	—	212,698
Intersegment sales	68,428	23	579	126	24	69,181	(69,181)	—
Total	106,900	54,081	58,759	47,577	14,561	281,880	(69,181)	212,698
Segment profit (loss)	20,879	5,032	4,618	3,921	1,867	36,320	(2,495)	33,824
Financial income	—	—	—	—	—	—	—	582
Financial expenses	—	—	—	—	—	—	—	963
Share of profit (loss) of associates accounted for using the equity method	—	—	—	—	—	—	—	(1,495)
Foreign exchange gain (loss)	—	—	—	—	—	—	—	1,351
Profit before tax	—	—	—	—	—	—	—	33,300
Income taxes expenses	—	—	—	—	—	—	—	11,145
Profit	—	—	—	—	—	—	—	22,154

Notes:

1. Segment profit (loss) adjustments of negative ¥2,495 million include negative ¥2,234 million for the unrealized gains on inventories and negative ¥258 million for the unrealized gains on non-current assets.
2. Segment profit (loss) is adjusted to coincide with operating profit in the condensed semi-annual consolidated statement of income.

Six months ended September 30, 2024

(Unit: Millions of yen)

	Reportable segment						Adjustments (Note 1)	Consolidated (Note 2)
	Head- quarters	Americas RHQ	EMEA RHQ	China RHQ	AP RHQ	Total		
Sales								
Sales to external customers	43,336	59,804	66,482	54,471	18,384	242,479	—	242,479
Intersegment sales	75,881	9	300	313	21	76,527	(76,527)	—
Total	119,218	59,814	66,782	54,785	18,405	319,007	(76,527)	242,479
Segment profit (loss)	27,595	3,178	6,785	5,812	3,740	47,111	(2,609)	44,502
Financial income	—	—	—	—	—	—	—	520
Financial expenses	—	—	—	—	—	—	—	1,421
Share of profit (loss) of associates accounted for using the equity method	—	—	—	—	—	—	—	(1,290)
Foreign exchange gain (loss)	—	—	—	—	—	—	—	(4,030)
Profit before tax	—	—	—	—	—	—	—	38,280
Income taxes expenses	—	—	—	—	—	—	—	12,357
Profit	—	—	—	—	—	—	—	25,923

Notes:

1. Segment profit (loss) adjustments of negative ¥2,609 million include negative ¥2,448 million for the unrealized gains on inventories and negative ¥161 million for the unrealized gains on non-current assets.
2. Segment profit (loss) is adjusted to coincide with operating profit in the condensed semi-annual consolidated statement of income.